



(51) International Patent Classification:

C07D 241/08 (2006.01) **A61K 31/499** (2006.01)
C07D 403/12 (2006.01) **A61K 31/495** (2006.01)
C07D 471/10 (2006.01) **A61P 25/28** (2006.01)
A61K 31/496 (2006.01)

(21) International Application Number:

PCT/IB2010/002340

(22) International Filing Date:

31 August 2010 (31.08.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09169036.2 31 August 2009 (31.08.2009) US

(71) Applicants: **INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PII SUNYER (IDIBAPS)** [ES/ES]; Villaroel, 170, E-08036 Barcelona (ES). **CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS** [ES/ES]; Serrano 113, E-28006 Madrid (ES).

(72) Inventors; and

(71) Applicants : **MORENO, Beatriz** [ES/ES]; Villaroel, 170, E-08036 Barcelona (ES). **VILLOSLADA, Pablo** [ES/ES]; Villaroel, 170, E-08036 Barcelona (ES). **MESSEGUER, Joaquin** [ES/ES]; Serrano 113, E-28006 Madrid (ES). **NAVARRO, Gloria** [ES/ES]; Serrano 113, E-28006 Madrid (ES). **MESSEGUER, Angel** [ES/ES]; Serrano 113, E-28006 Madrid (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: 3 -OXOPIPERAZINIUM DERIVATIVES AS AGONISTS OF NERVE GROWTH FACTOR AND THEIR USE AS MEDICAMENTS

(57) Abstract: New 3-oxopiperazinium derivatives agonists of Nerve Growth Factor receptors and their use as medicaments. Neurotrophin binding to its specific receptor Trk A leads to the activation of multiple signalling cascades, culminating in neuroregenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin peptidomimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules derived from the 3-oxopiperazinium scaffold to induce differentiation in PC12 cells and, therefore, that these small molecules with NGF agonist activity may be beneficial for treatment of neurodegenerative diseases, due to their neuroregenerative effects.



3-OXOPIPERAZINIUM DERIVATIVES AS AGONISTS OF NERVE GROWTH FACTOR AND THEIR USE
AS MEDICAMENTS

The present application claims priority to European Patent Application No.
5 09169036.2, filed August 31, 2009. The full disclosure of this application is herein
incorporated by reference.

BACKGROUND OF THE INVENTION

Field of invention

This invention applies to the area of therapeutics for neurological, psychiatric
10 disorders, and ageing. In particular, it relates to the neuroprotective effect of small
molecule agonists of neurotrophin (Nerve Growth Factor –NGF-) receptor and the use
of those agonists as medicaments.

Background art

15 Ageing, neurological and psychiatric disorders cause death and damage to nerve cells.
Frequent and relevant damage to the nervous system can result from neuronal
degeneration, ischemia, inflammation, immune responses, trauma, and cancer, among
other things. As a consequence of these, nerve cells can die within minutes or hours
or survive this initial damage in an impaired state that activates neurodegeneration,
20 ending equally in cellular death.

Given the importance of the nervous system in enabling basic motor skills and
sensing, there exists an interest in finding therapeutic weapons to protect the nervous
system.

25 Neuroprotection is focused on the preservation, recovery, cure, or regeneration of the
nervous system, its cells, structure, and function (Vajda et al., 2002). A goal of
neuroprotection is to prevent or minimize the effects of an original damage to the
nervous system, or to prevent or minimize the consequences of endogenous or

exogenous noxious processes causing damage to axons, neurons, synapses, and dendrites.

Treatment strategies in general are frequently based on the modulation of a single
5 proposed injury factor. Although such treatments can be shown to be beneficial in
highly constrained animal models, they are less likely to prove efficacious in the more
complex human disorder that involves more variable degrees of injury severity in a
genetically diverse population (Faden and Stoica, 2007). Importantly, since the
presumed mechanisms of neuronal death are both complex and varied, such as
10 oxidative stress, mitochondrial dysfunction, protein aggregation, apoptosis, and
inflammation (Youdim et al., 2005), single compounds having multipotential effects
on multiple injury mechanisms are desirable.

Several neuroprotective drugs are under investigation including the following classes:
15 anti-inflammatory agents, N-methyl D-aspartate (NMDA) antagonists, α -amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) antagonists, dexamethasone,
sodium channel blockers, thyrotropin-releasing hormone (TRH), growth factors,
glucocorticoids, caffeine, opioid antagonists, apoptosis inhibitors, free radical
trappers/scavengers, erythropoietin, calcium channel blockers, magnesium sulfate,
20 statins.

The ability of these pharmacological agents to limit secondary biochemical damage
and cell death has been disappointing (Faden and Stoica, 2007).

25 Neurotrophins are growth factors that regulate the development and maintenance of
the peripheral and the central nervous systems (Lewin and Barde, 1996). Nerve
growth factor (NGF) is a homodimeric protein from the neurotrophin family that plays
a crucial role in neuronal survival, differentiation and growth (Levi-Montalcini, 1987)
and binds two distinct cellular receptors: the tyrosine kinase receptor TrkA and the
30 p75 receptor (Chao, 2003). NGF-TrkA binding activates the intrinsic tyrosine kinase
of the receptor, causing tyrosine phosphorylation of TrkA and associated signalling
partners and therefore activating promotion of cell survival or differentiation (Kaplan

and Miller, 2000). The p75 receptor is a member of the tumor necrosis factor receptor superfamily. Depending on the cellular environment and the type of ligand, p75 can act as transducer of pro-survival, pro-apoptotic, or pro-differentiation signals (Barker, 1998; Rabizadeh et al., 1999; Zaccaro et al., 2001; Saragovi and Zaccaro, 2002).
5 Accordingly, depending on the metabolic route, binding to either TrkA or p75 receptors may trigger signals, depending on the cell type considered, linked to, indistinctly, differentiation and/or cell survival.

The potential of NGF as a therapeutic agent for several diseases has been indicated by
10 several investigators. Such diseases include neurodegenerative disorders, nerve inflammation and certain types of cancers, multiple sclerosis, neuromyelitis optica, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Friedreich's ataxia, Huntington's disease, Dementia with Lewy bodies, spinal muscular atrophy, major depressive disorder, schizophrenia, glaucoma or peripheral
15 neuropathies (diabetic or AIDS neuropathy) (Longo et al, 2007; Schulte-Herbrüggen, 2007; Shi, 2007; Hellveg, 2008; Shoval, 2005; Apfel, 2002; Anand, 2004). NGF has significant immunoregulatory properties during CNS inflammation to contribute to the maintenance of the CNS privilege (Villoslada and Genain, 2004). During Experimental Autoimmune Encephalomyelitis (EAE) in marmoset, NGF was able to
20 inhibit the development of the clinical symptoms when administered intracerebroventricularly by continuous infusion apparently because of its ability to induce an immunosuppressive microenvironment in the CNS which leads to decreased CNS infiltration (Villoslada et al., 2000). The finding that NGF induces immunosuppression during autoimmune demyelination in addition to its
25 neuroprotective properties in neurons and oligodendrocytes makes it a very good candidate for the treatment of CNS inflammatory diseases like MS. However, NGF is not the ideal drug candidate due to its inability to cross the blood-brain barrier (BBB) (Poduslo and Curran, 1996), its short half life and its side effects (Apfel, 2002). Much effort has been made in the search for small molecules with NGF agonist activity,
30 with better pharmacokinetics and less side effects. To achieve this goal, different approaches have been attempted (Poduslo and Curran, 1996; Longo et al., 1997; Maliartchouk et al., 2000a; Maliartchouk et al., 2000b; Peleshok and Saragovi, 2006).

As such, there is an ongoing need for providing drugs, particularly NGF mimetics, with neuroprotective properties, which have preferably multipotential effects, but without the drawbacks of NGF. The present inventors have developed a family of compounds distinct from those disclosed in the art. The family of compounds of the invention are peptidomimetics of NGF, and agonists to Trk A specific receptor binding. They are 3-oxopiperazinium derivatives which share a cation charge due to a tetrasubstituted nitrogen atom present in its structure.

SUMMARY OF THE INVENTION

The present invention is related to the use of compounds of Formulae I-IV, below, and the pharmaceutically acceptable salts and prodrugs thereof, as agonists of nerve growth factor (NGF) receptors.

One aspect of the present invention is directed to compounds of any of Formulae I-IV, as well as their pharmaceutically acceptable salts and prodrugs.

Another aspect of the invention is directed to the use of compounds of any of Formulae I-IV, and their pharmaceutically acceptable salts and prodrugs, as agonists of NGF receptors.

A further aspect of the invention is to provide a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, for use as a medicament. In one aspect of the invention, the medicament is for use in preventing or treating nerve cell death or damage. In one aspect of the invention, the medicament is for use in neuroprotection. In one aspect of the invention, the medicament is for use in regeneration of nerve cells. In one aspect of the invention, the medicament is for use in neuroenhancing. In one aspect, the medicament is for use in preventing or treating a neurological or a psychiatric disease. In one aspect of the invention, the medicament is for use in preventing or treating a disease selected from the group consisting of a neurological disease, a preferentially neurodegenerative disorder (such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Friedreich's ataxia,

Huntington's disease, Dementia with Lewy bodies, and spinal muscular atrophy), nerve inflammation (such as multiple sclerosis and neuromyelitis optica), major depressive disorder, schizophrenia, glaucoma, peripheral neuropathy (such as diabetic or AIDS neuropathy), and cancer (such as glioblastoma, astrocytoma, meduloblastoma, neurinoma, neuroblastoma, meningioma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, leukemia, acute lymphocytic leukemia, osteosarcoma, hepatocellular carcinoma, ovarian carcinoma, lung adenocarcinoma, and esophagic carcinoma).

10 A further aspect of the present invention is to provide a pharmaceutical composition, comprising a therapeutically effective amount of at least one compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.

15 A further aspect of the invention is to provide the use of a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for preventing or treating nerve cell death or damage.

A further aspect of the invention is to provide the use of a compound of any of
20 Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for providing neuroprotection.

A further aspect of the invention is to provide the use of a compound of any of
25 Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for the regeneration of nerve cells.

A further aspect of the invention is to provide the use of a compound of any of
30 Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for preventing or treating a neurological disease or a psychiatric disease.

A further aspect of the invention is to provide the use of a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for preventing or treating a disease selected from the group consisting of a neurological disease, a preferentially neurodegenerative disorder (such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Friedreich's ataxia, Huntington's disease, Dementia with Lewy bodies, and spinal muscular atrophy), nerve inflammation (such as multiple sclerosis and neuromyelitis optica), major depressive disorder, schizophrenia, glaucoma, peripheral neuropathy (such as diabetic or AIDS neuropathy), and cancer (such as glioblastoma, astrocytoma, meduloblastoma, neurinoma, neuroblastoma, meningioma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, leukemia, acute lymphocytic leukemia, osteosarcoma, hepatocellular carcinoma, ovarian carcinoma, lung adenocarcinoma, and esophagic carcinoma).

A further aspect of the invention is to provide a method for preventing or treating nerve cell death or damage, comprising administering to a subject in need thereof an effective amount of a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, or an effective amount of a pharmaceutical composition comprising a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof.

A further aspect of the invention is to provide a method for providing neuroprotection, comprising administering to a subject in need thereof an effective amount of a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, or an effective amount of a pharmaceutical composition comprising a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof.

A further aspect of the invention is to provide a method for regenerating nerve cells, comprising administering to a subject in need thereof an effective amount of a compound of any of Formulae I-IV (and specifically a compound of Formula II), or a pharmaceutically acceptable salt or prodrug thereof, or an effective amount of a

pharmaceutical composition comprising a compound of any of Formulae I-IV (and specifically a compound of Formula II), or a pharmaceutically acceptable salt or prodrug thereof.

5 A further aspect of the invention is to provide a method for preventing or treating a disease selected from the group consisting of a neurological disease, a preferentially neurodegenerative disorder (such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Friedreich's ataxia, Huntington's disease, Dementia with Lewy bodies, and spinal muscular atrophy), nerve inflammation (such as
10 multiple sclerosis and neuromyelitis optica), major depressive disorder, schizophrenia, glaucoma, peripheral neuropathy (such as diabetic or AIDS neuropathy), and cancer (such as glioblastoma, astrocytoma, meduloblastoma, neurinoma, neuroblastoma, meningioma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, leukemia, acute lymphocytic leukemia, osteosarcoma, hepatocellular carcinoma, ovarian
15 carcinoma, lung adenocarcinoma, and esophagic carcinoma), comprising administering to a subject in need thereof an effective amount of a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, or an effective amount of a pharmaceutical composition comprising a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof.

20 A further aspect of the invention is to provide a method of treating a disease responsive to the stimulation of the activity of nerve growth factor, or a nerve growth factor receptor, in a mammal suffering from lack of stimulation thereof, comprising administering an effective amount a compound of any of Formulae I-IV, or a
25 pharmaceutically acceptable salt or prodrug thereof.

A further aspect of the invention is to provide a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, for use in stimulating the activity of nerve growth factor, or a nerve growth factor receptor.

30 A further aspect of the present invention is to provide a method of stimulating nerve growth factor receptor activity in a subject in need thereof, comprising administering a

compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, to the subject. In one embodiment, the nerve growth factor receptor is TrkA receptor or p75 receptor.

5 A further aspect of the present invention is to provide a method of preparing a pharmaceutical composition, comprising admixing an effective amount of a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt or prodrug thereof, with a pharmaceutically acceptable carrier.

10 Additional embodiments and advantages of the invention will be set forth in part in the description that follows, and will flow from the description, or may be learned by practice of the invention. The embodiments and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.

15

It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only and not restrictive of the invention as claimed.

BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES

20 Fig. 1 depicts induction of PC12 cells differentiation by NGF-like molecules. Differentiation levels induced after 3 days of treatment with the 3-oxopiperazinium derivatives: A26-23, A26-64 and A28-A6. Data are expressed as percentage of the differentiation (cells with neurite processes at least 2 times the diameter of the cell body) induced by NGF. Data are the mean $\pm$ SEM of at least three experiments, each
25 in duplicate. * $p < 0.05$, ** $p < 0.01$ (ANOVA) with regard to the control.

FIG. 2 shows effects of NGF-like molecules in promotion of RN22 cell survival. RN22 schwannoma cells in serum free medium were treated with copper sulphate (CuSO₄) (150 μ M) to generate stress and cell death. After that NGF (100 ng/ml) or
30 NGF-like small compounds derived from 3-oxopiperazinium: A26-23, A26-64 and A28-A6 were added at different concentrations. Cell viability was analyzed by MTT

assay 24 h later. Depicted are the means $\pm$ S.E. of three experiments, each in duplicate. * $p < 0.05$, ** $p < 0.01$ (ANOVA) respect to stress control.

DETAILED DESCRIPTION OF THE INVENTION


One aspect of the invention is based on the use of compounds of Formulae I-IV, and the pharmaceutically acceptable salts and prodrugs thereof, as agonists of nerve growth factor (NGF) receptors. In view of this property, compounds of Formulae I-IV, and the pharmaceutically acceptable salts and prodrugs thereof, are useful for preventing or treating diseases responsive to the stimulation of nerve growth factor, or a nerve growth factor receptor.

10

The invention uses a library (Masip et al., 2004) of tetraalkylammonium heterocyclic compounds, (100 individual molecules).



The compounds useful in this aspect of the invention are the compounds represented by Formula I:

15



and pharmaceutically acceptable salts and prodrugs thereof, wherein R_1 is nitrophenyl or 5-methylindolyl, and R_2 and R_3 are each independently benzyl or CH_3 as follows:

20



or R_2 and R_3 form together with the 3-oxopiperazinium ring a fused azoniosapiro [4,5] decane heterocycle.

In one embodiment, compounds useful in the present invention are compounds of
5 Formula I, wherein R_1 is nitrophenyl. In one embodiment, the nitrophenyl group is 2-nitrophenyl, 3-nitrophenyl, or 4-nitrophenyl. Preferably, R_1 is 4-nitrophenyl.

In one embodiment, compounds useful in the present invention are compounds of
Formula I, wherein R_1 is 5-methylindolyl. In one embodiment, the 5-methylindolyl
10 group is 5-methylindol-2-yl, 5-methylindol-3-yl, 5-methylindol-4-yl, 5-methylindol-6-yl or 5-methylindol-7-yl, and preferably 5-methylindol-2-yl.


In one embodiment, compounds useful in the present invention are compounds of
Formula I, wherein R_2 and R_3 both are benzyl.
15

In another embodiment, compounds useful in the present invention are compounds of
Formula I, wherein R_2 and R_3 both are CH_3 .

In another embodiment, compounds useful in the present invention are compounds of
20 Formula I, wherein R_2 is CH_3 and R_3 is benzyl.



In one embodiment, compounds useful in the present invention are compounds of
Formula I, wherein R_2 and R_3 form together with the 3-oxopiperazinium ring a fused
azoniosapiro [4,5] decane heterocycle.
25

In one embodiment, compounds useful in the present invention are compounds having
the Formula I:



and pharmaceutically acceptable salts and prodrugs thereof,


wherein R_1 is 4-nitrophenyl or 5-methylindol-2-yl, and R_2 and R_3 are each independently benzyl or CH_3 as follows:



or R_2 and R_3 form together with the 3-oxopiperazinium ring a fused azoniosapir [4,5] decane heterocycle.

From the tested molecules the invention selected 3 compounds which showed a good
10 NGF like activity “in vitro” by inducing differentiation of PC12 cells and, therefore, having neuroregenerative properties.

Accordingly, preferred compounds according to present invention are those of Formula I in which, when



15


then R_2 and R_3 are each one independently CH_3 ; or R_2 is CH_3 and R_3 is benzyl.

Also preferred compounds according to the present invention are those of Formula I, wherein when R_1 is 5-methylindolyl, then R_2 and R_3 form together with the 3-oxopiperazinium ring a fused azoniasapir [4,5] decane heterocycle.
20

The invention also covers pharmaceutically acceptable salts and/or prodrugs of the above mentioned preferred compounds of Formula I.


- 5 As a way of example, preferred compounds according to present invention are selected among the following:

Formula II:



- 10 1,1- dimethyl -4- [2-(4-nitrophenethylamino) -2- oxoethyl] -3-oxopiperazin-2-ium chloride (A26-23);

Formula III:




15

1-benzyl-1-methyl-4-[2-(4-nitrophenethylamino)-2-oxoethyl]-3-oxopiperazin-2-ium chloride (A26-64); and

20

Formula IV:



8-[2-(2-(5-methyl-1H-indol-2-yl)ethylamino)-2-oxoethyl]-7-oxo-8-aza-5-azoniaspiro[4.5]decane. (A28-A6);
and pharmaceutically acceptable salts and/or prodrugs thereof.

- 5 In one embodiment, the compound of Formula I is the compound of Formula II, or a pharmaceutically acceptable salt or prodrug thereof.

In one embodiment, the compound of Formula I is the compound of Formula III, or a pharmaceutically acceptable salt or prodrug thereof.

10

In one embodiment, the compound of Formula I is the compound of Formula IV, or a pharmaceutically acceptable salt or prodrug thereof.

- 15 The term “prodrug”, as used herein, includes any compound derived from the compounds of any of Formulae I-IV, for example, the ester, amide, phosphate, etc., which, upon being administered to an individual, is capable of providing the compounds of any of Formulae I-IV or the pharmaceutically acceptable salt thereof, directly or indirectly, to said individual. Preferably, said derivative is a compound that increases the bioavailability of the compounds of any of Formulae I-IV when
20 administered to an individual or that promotes the release of the compounds of any of Formulae I-IV in a biological compartment. The nature of said derivative is not critical, provided that it may be administered to an individual and that it provides the compounds of any of Formulae I-IV in an individual’s biological compartment. The preparation of said prodrug may be performed by conventional methods known by
25 those skilled in the art. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, *Design of Prodrugs*, H. Bundgaard ed., Elsevier (1985). An example of prodrug of the compounds of Formula I can be their encapsulation into liposomes.

- 30 The term “pharmaceutically acceptable” means that a compound or combination of compounds is sufficiently compatible with the other ingredients of a formulation, and not deleterious to the patient up to those levels acceptable by the industry standards.

For therapeutic use, salts of the compounds of any of Formulae I-IV are those wherein the counter-ion is pharmaceutically acceptable.

- 5 The term salt as mentioned herein is meant to comprise any stable salts, which the compounds of any of Formulae I-IV are able to form. Preferred are the pharmaceutically acceptable salts. Salts that are not pharmaceutically acceptable are also embraced in the scope of the present invention, since they refer to intermediates that may be useful in the preparation of compounds with pharmacological activity.

10

The salts can conveniently be obtained by treating the base form of the compounds of Formula I with such appropriate acids as inorganic acids such as hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. 15 ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic (i.e. hydroxybutanedioic acid), tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.

- 20 The pharmaceutically acceptable salts can be obtained by treating the base form of the compounds of any of Formulae I-IV with such appropriate pharmaceutically acceptable acids like inorganic acids, for example, including hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy- 25 1,2,3-propane-tricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzene-sulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids.

- 30 Conversely the salt form can be converted by treatment with alkali into the free base form.

The term "pharmaceutical composition" means for the purpose of the present invention any composition which comprises as an active compound, to which is attributed, fully or in part, the therapeutic (e.g. pharmaceutical) effect, at least one of the compounds of the invention or combinations thereof and that may optionally
5 further comprise at least one pharmaceutically acceptable non-active ingredient, as an excipient, carrier or so.

The term "preventing" refers to keep from happening, existing, or alternatively delaying the onset or recurrence of a disease, disorder, or condition to which such
10 term applies, or of one or more symptoms associated with a disease, disorder, or condition. The term "prevention" refers to the act of preventing, as "preventing" is defined immediately above.

The term "treating", as used herein, refers to reversing, alleviating, or inhibiting the
15 progress of the disorder or condition to which such term applies, or one or more symptoms of such disorders or condition. The term "treatment" refers to the act of treating, as "treating" is defined immediately above.

The term "subject" means animals, in particular mammals such as dogs, cats, cows,
20 horses, sheep, geese, and humans. Particularly preferred subjects are mammals, including humans of both sexes.

An "effective amount" of the compounds of any of Formulae I-IV and pharmaceutically acceptable salts or prodrugs thereof, may be in the range from 0.01
25 mg to 50 g per day, from 0.02 mg to 40 g per day, from 0.05 mg to 30 g per day, from 0.1 mg to 20 g per day, from 0.2 mg to 10 g per day, from 0.5 mg to 5 g per day, from 1 mg to 3 g per day, from 2 mg to 2 g per day, from 5 mg to 1,5 g per day, from 10 mg to 1 g per day, from 10 mg to 500 mg per day.

30 Nerve cells include those cells from any region of the brain, spinal cord, optic nerve, retina, and peripheral ganglia. Neurons include those in embryonic, fetal, or adult neural tissue, including tissue from the hippocampus, cerebellum, spinal cord, cortex

(e.g., motor or somatosensory cortex), striatum, basal forebrain (cholinergic neurons), ventral mesencephalon (cells of the substantia nigra), and the locus ceruleus (neuroadrenaline cells of the central nervous system).

- 5 The invention also covers the use of the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, as active ingredients in the manufacture of medicaments for the prevention or treatment of nerve cell death or damage. In other words, the present invention relates to the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, for use
- 10 in the prevention or treatment of nerve cell death or damage. Similarly, the present invention relates to a method of neuroprotection comprising administering to a subject in need thereof an effective amount of a compound of any of Formulae I-IV, or pharmaceutically acceptable salts and/or prodrugs thereof.
- 15 In one embodiment of the present invention, the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, may be used for the prevention or treatment of one or more, preferably two or more, pathological or harmful conditions related to nerve cell death or damage selected from, but not being limited to, chemical substances such as oxidative stress conditions, toxic substances,
- 20 infectious organisms, radiation, traumatic injury, hypoxia, ischemia, abnormal misfolded proteins, excitotoxins, free radicals, endoplasmic reticulum stressors, mitochondrial stressors including but not limited to inhibitors of the electron transport chain, Golgi apparatus antagonists, axonal damage or loss, demyelination, inflammation, pathological neuronal burst (seizures). Also preferably, the uses and
- 25 methods of the present invention are directed to preventing or treating nerve cell death or damage, regardless of cause.

The terms “neuroprotection”, “neuroprotective”, or “neuroprotective effect” refer to the ability to prevent or reduce death or damage to nerve cells, including neurons and

30 glia, or rescuing, resuscitating or reviving nerve cells, e.g., following in pathological or harmful conditions to the brain, central nervous system or peripheral nervous system. Thus, this neuroprotective effect comprises the conferred ability of neuronal

cells to maintain or recover their neuronal functions. It stabilizes the cell membrane of a neuronal cell or helps in the normalization of neuronal cell functions. It prevents the loss of viability or functions of neuronal cells. It comprises the inhibition of progressive deterioration of neurons that leads to cell death. It refers to any detectable protection of neurons from stress. Neuroprotection includes the regeneration of nerve cells, i.e. the re-growth of a population of nerve cells after disease or trauma.

Currently the majority of the neurological and psychiatric diseases lacks specific treatments aimed to stop or ameliorate the course of the disease, which are called “disease modifying drugs”. This contrast with the symptomatic therapies which are common for such diseases but do not change the course of the disease. A neuroprotective drug is a Disease Modifying Drug (DMD) for the treatment of brain diseases.

As such, in one embodiment, the present invention relates to the use of the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, as active ingredients in the manufacture of a medicament for the regeneration of nerve cells. In other words, the present invention relates to the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, for use for the regeneration of nerve cells. Similarly, the present invention relates to a method of regenerating nerve cells comprising administering to a subject in need thereof an effective amount of a compound of any of Formulae I-IV, or a pharmaceutically acceptable salt and/or prodrug thereof.

Neuroprotection may be determined directly by, for example, measuring the delay or prevention of neuronal death, such as, for example, by a reduction in the number of apoptotic neurons in cerebrocortical cultures following a stress. Neuroprotection may also be determined directly by, for example, measuring the severity or extent of damage to, or functional loss by, a tissue or organ of the nervous system following such a stress, such as, for example, by measuring a decrease in the size of brain infarcts after occlusion of the middle cerebral artery (MCAO) or reperfusion injury. Also, neuroprotection can be identified by magnetic resonance imaging (measuring

brain volume, tractography, levels of N-acetyl-aspartate by spectroscopy). Alternatively, neuroprotection may be determined indirectly by detecting the activation of one or more biological mechanisms for protecting neurons, including, but not limited to, detecting activation of the Keap1/Nrf2 pathway or induction of one or more phase 2 enzymes, including but not limited to hemeoxygenase-1 (HO-1). Methods of detecting and measuring neuronal protection are provided in the Examples below, and other such methods are known in the art.

The various uses and methods employing the compounds of any of Formulae I-IV, and pharmaceutically salts and/or prodrugs thereof in the present invention comprise acute administration, i.e. occurring within several minutes to about several hours from injury, or chronic administration, suitable for chronic neurological or psychiatric diseases.

In one embodiment of the present invention, in the various uses and methods of neuroprotection or of prevention or treatment of nerve cell death or damage, the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, are administered to a subject with a neurological or psychiatric disease.

Neurological diseases are those disorders of the central and peripheral nervous system, including disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.

Diseases of the central and peripheral nervous system, which may be subject of prevention and/or treatment according to present invention include, without being limited to, as knowledge in clinical manifestations advances, Absence of the Septum Pellucidum, Acid Lipase Disease, Acid Maltase Deficiency, Acquired Epileptiform Aphasia, Acute Disseminated Encephalomyelitis, Adie's Pupil, Adie's Syndrome, Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Agnosia, Aicardi Syndrome, Aicardi-Goutieres Syndrome Disorder, AIDS - Neurological Complications, Alexander Disease, Alpers' Disease, Alternating Hemiplegia,

Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anencephaly, Aneurysm, Angelman Syndrome, Angiomatosis, Anoxia, Antiphospholipid Syndrome, Aphasia, Apraxia, Arachnoid Cysts, Arachnoiditis, Arnold-Chiari Malformation, Arteriovenous Malformation, Asperger Syndrome, Ataxia, Ataxia Telangiectasia, Ataxias and
5 Cerebellar or Spinocerebellar Degeneration, Atrial Fibrillation and Stroke, Attention Deficit-Hyperactivity Disorder (ADHD), Autism, Autonomic Dysfunction, Back Pain, Barth Syndrome, Batten Disease, Becker's Myotonia, Behcet's Disease, Bell's Palsy, Benign Essential Blepharospasm, Benign Focal Amyotrophy, Benign Intracranial Hypertension, Bernhardt-Roth Syndrome, Binswanger's Disease, Blepharospasm,
10 Bloch-Sulzberger Syndrome, Brachial Plexus Birth Injuries, Brachial Plexus Injuries, Bradbury-Eggleston Syndrome, Brain and Spinal Tumors, Brain Aneurysm, Brain infarction, Brain ischemia, Brain Injury, Brown-Sequard Syndrome, Bulbosplinal Muscular Atrophy, CADASIL, Canavan Disease, Carpal Tunnel Syndrome, Causalgia, Cavernomas, Cavernous Angioma, Cavernous Malformation, Central
15 Cervical Cord Syndrome, Central Cord Syndrome, Central Pain Syndrome, Central Pontine Myelinolysis, Cephalic Disorders, Ceramidase Deficiency, Cerebellar Degeneration, Cerebellar Hypoplasia, Cerebral Aneurysm, Cerebral Arteriosclerosis, Cerebral Atrophy, Cerebral Beriberi, Cerebral Cavernous Malformation, Cerebral Gigantism, Cerebral Hypoxia, Cerebral Palsy, Cerebro-Oculo-Facio-Skeletal
20 Syndrome, Charcot-Marie-Tooth Disease, Chiari Malformation, Cholesterol Ester Storage Disease, Chorea, Choreoacanthocytosis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Chronic Orthostatic Intolerance, Chronic Pain, Cockayne Syndrome Type II, Coffin Lowry Syndrome, COFS, Colpocephaly, Coma, Complex Regional Pain Syndrome, Congenital Facial Diplegia, Congenital
25 Myasthenia, Congenital Myopathy, Congenital Vascular Cavernous Malformations, Corticobasal Degeneration, Cranial Arteritis, Craniosynostosis, Creutzfeldt-Jakob Disease, Cumulative Trauma Disorders, Cushing's Syndrome, Cytomegalic Inclusion Body Disease, Cytomegalovirus Infection, Dancing Eyes-Dancing Feet Syndrome, Dandy-Walker Syndrome, Dawson Disease, De Morsier's Syndrome, Deep Brain
30 Stimulation for Parkinson's Disease, Dejerine-Klumpke Palsy, Dementia, Dementia - Multi-Infarct, Dementia - Semantic, Dementia - Subcortical, Dementia With Lewy Bodies, Dentate Cerebellar Ataxia, Dentatorubral Atrophy, Dermatomyositis,

Developmental Dyspraxia, Devic's Syndrome, Diabetic Neuropathy, Diffuse Sclerosis, Dravet Syndrome, Dysautonomia, Dysgraphia, Dyslexia, Dysphagia, Dyspraxia, Dyssynergia Cerebellaris Myoclonica, Dyssynergia Cerebellaris Progressiva, Dystonias, , Early Infantile Epileptic Encephalopathy, Empty Sella
 5 Syndrome, Encephalitis, Encephalitis Lethargica, Encephaloceles, Encephalopathy, Encephalopathy, familial infantile, with intracranial calcification and chronic cerebrospinal fluid lymphocytosis; Cree encephalitis; Pseudo-Torch syndrome; Pseudotoxoplasmosis syndrome, Encephalotrigeminal Angiomatosis, Epilepsy, Epileptic Hemiplegia, Erb-Duchenne and Dejerine-Klumpke Palsies, Erb's Palsy,
 10 Essential Tremor, Extrapontine Myelinolysis, Fabry Disease, Fahr's Syndrome, Fainting, Familial Dysautonomia, Familial Hemangioma, Familial Idiopathic Basal Ganglia Calcification, Familial Periodic Paralysis, Familial Spastic Paralysis, Farber's Disease, Febrile Seizures, Fibromuscular Dysplasia, Fisher Syndrome, Floppy Infant Syndrome, Foot Drop, Friedreich's Ataxia, Frontotemporal Dementia ,
 15 Gangliosidoses, Gaucher's Disease, Gerstmann's Syndrome, Gerstmann-Straussler-Scheinker Disease, Giant Axonal Neuropathy, Giant Cell Arteritis, Giant Cell Inclusion Disease, Globoid Cell Leukodystrophy, Glossopharyngeal Neuralgia, Glycogen Storage Disease, Guillain-Barré Syndrome, Hallervorden-Spatz Disease, Head Injury, Headache, Hemicrania Continua, Hemifacial Spasm, Hemiplegia
 20 Alterans, Hereditary Neuropathies, Hereditary Spastic Paraplegia, Heredopathia Atactica Polyneuritiformis, Herpes Zoster, Herpes Zoster Oticus, Hirayama Syndrome, Holmes-Adie syndrome , Holoprosencephaly, HTLV-1 Associated Myelopathy, Hughes Syndrome, Huntington's Disease, Hydranencephaly, Hydrocephalus, Hydrocephalus - Normal Pressure, Hydromyelia, Hypercortisolism,
 25 Hypersomnia, Hypertonia, Hypotonia, Hypoxia, Immune-Mediated Encephalomyelitis, Inclusion Body Myositis, Incontinentia Pigmenti, Infantile Hypotonia, Infantile Neuroaxonal Dystrophy , Infantile Phytanic Acid Storage Disease, Infantile Refsum Disease, Infantile Spasms, Inflammatory Myopathies, Iniencephaly, Intestinal Lipodystrophy, Intracranial Cysts, Intracranial Hypertension,
 30 Isaac's Syndrome, Joubert Syndrome, Kearns-Sayre Syndrome, Kennedy's Disease, Kinsbourne syndrome, Kleine-Levin Syndrome, Klippel-Feil Syndrome, Klippel-Trenaunay Syndrome (KTS), Klüver-Bucy Syndrome, Korsakoff's Amnesic

Syndrome, Krabbe Disease, Kugelberg-Welander Disease, Kuru, Lambert-Eaton Myasthenic Syndrome, Landau-Kleffner Syndrome, Lateral Femoral Cutaneous Nerve Entrapment, Lateral Medullary Syndrome, Learning Disabilities, Leigh's Disease, Lennox-Gastaut Syndrome, Lesch-Nyhan Syndrome, Leukodystrophy, Levine-
5 Critchley Syndrome, Lewy Body Dementia, Lipid Storage Diseases, Lipoid Proteinosis, Lissencephaly, Locked-In Syndrome, Lou Gehrig's Disease, Lupus - Neurological Sequelae, Lyme Disease - Neurological Complications, Machado-Joseph Disease, Macrencephaly, Megalencephaly, Melkersson-Rosenthal Syndrome, Meningitis, Meningitis and Encephalitis, Menkes Disease, Meralgia Paresthetica,
10 Metachromatic Leukodystrophy, Microcephaly, Migraine, Miller Fisher Syndrome, Mild Cognitive Impairment, Mini-Stroke, Mitochondrial Myopathies, Moebius Syndrome, Monomelic Amyotrophy, Motor Neuron Diseases, Moyamoya Disease, Mucopolysaccharidoses, Multifocal Motor Neuropathy, Multi-Infarct Dementia, Multiple Sclerosis, Multiple System Atrophy, Multiple System Atrophy
15 with Orthostatic Hypotension, Muscular Dystrophy, Myasthenia - Congenital, Myasthenia Gravis, Myelinoclastic Diffuse Sclerosis, Myoclonic Encephalopathy of Infants, Myoclonus, Myopathy, Myopathy - Congenital, Myopathy - Thyrotoxic, Myotonia, Myotonia Congenita, Narcolepsy, Neuroacanthocytosis, Neurodegeneration with Brain Iron Accumulation, Neurofibromatosis, Neuroleptic
20 Malignant Syndrome, Neurological Complications of AIDS, Neurological Complications of Lyme Disease, Neurological Consequences of Cytomegalovirus Infection, Neurological Manifestations of Pompe Disease, Neurological Sequelae Of Lupus, Neuromyelitis Optica , Neuromyotonia, Neuronal Ceroid Lipofuscinosis, Neuronal Migration Disorders, Neuropathy - Hereditary, Neurosarcoidosis,
25 Neurotoxicity, Nevus Cavemosus, Niemann-Pick Disease, Normal Pressure Hydrocephalus, Occipital Neuralgia, Ohtahara Syndrome, Olivopontocerebellar Atrophy, Opsoclonus Myoclonus, Orthostatic Hypotension, O'Sullivan-McLeod Syndrome, Overuse Syndrome, Pain - Chronic, Pantothenate Kinase-Associated Neurodegeneration, Paraneoplastic Syndromes, Paresthesia, Parkinson's Disease,
30 Paroxysmal Choreoathetosis, Paroxysmal Hemicrania, Parry-Romberg, Pelizaeus-Merzbacher Disease, Pena Shokeir II Syndrome, Perineural Cysts, Periodic Paralysis, Peripheral Neuropathy, Periventricular Leukomalacia, Persistent Vegetative State,

Pervasive Developmental Disorders, Phytanic Acid Storage Disease, Pick's Disease, Pinched Nerve, Piriformis Syndrome, Pituitary Tumors, Polymyositis, Pompe Disease, Porencephaly, Postherpetic Neuralgia, Postinfectious Encephalomyelitis, Post-Polio Syndrome, Postural Hypotension, Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Primary Dentatum Atrophy, Primary Lateral Sclerosis, Primary Progressive Aphasia, Prion Diseases, Progressive Hemifacial Atrophy, Progressive Locomotor Ataxia, Progressive Multifocal Leukoencephalopathy, Progressive Sclerosing Poliodystrophy, Progressive Supranuclear Palsy, Prosopagnosia, Pseudotumor Cerebri, Ramsay Hunt Syndrome I (formerly known as dyssynergia cerebellaris myoclonica, dyssynergia cerebellaris progressiva, dentatorubral degeneration, or Ramsey Hunt cerebellar syndrome), Ramsay Hunt Syndrome II (formerly known as herpes zoster oticus), Rasmussen's Encephalitis, Reflex Sympathetic Dystrophy Syndrome, Refsum Disease, Refsum Disease - Infantile, Repetitive Motion Disorders, Repetitive Stress Injuries, Restless Legs Syndrome, Retrovirus-Associated Myelopathy, Rett Syndrome, Reye's Syndrome, Rheumatic Encephalitis, Riley-Day Syndrome, Sacral Nerve Root Cysts, Saint Vitus Dance, Salivary Gland Disease, Sandhoff Disease, Schilder's Disease, Schizencephaly, Seitelberger Disease, Seizure Disorder, Semantic Dementia, Septo-Optic Dysplasia, Severe Myoclonic Epilepsy of Infancy (SMEI), Shaken Baby Syndrome, Shingles, Shy-Drager Syndrome, Sjögren's Syndrome, Sleep Apnea, Sleeping Sickness, Sotos Syndrome, Spasticity, Spina Bifida, Spinal Cord Infarction, Spinal Cord Injury, Spinal Cord Tumors, Spinal Muscular Atrophy, Spinocerebellar Atrophy, Spinocerebellar Degeneration, Steele-Richardson-Olszewski Syndrome, Stiff-Person Syndrome, Striatonigral Degeneration, Stroke, Sturge-Weber Syndrome, Subacute Sclerosing Panencephalitis, Subcortical Arteriosclerotic Encephalopathy, SUNCT Headache, Swallowing Disorders, Sydenham Chorea, Syncope, Syphilitic Spinal Sclerosis, Syringohydromyelia, Syringomyelia, Systemic Lupus Erythematosus, Tabes Dorsalis, Tardive Dyskinesia, Tarlov Cysts, Tay-Sachs Disease, Temporal Arteritis, Tethered Spinal Cord Syndrome, Thomsen's Myotonia, Thoracic Outlet Syndrome, Thyrotoxic Myopathy, Tic Douloureux, Todd's Paralysis, Tourette Syndrome, Transient Ischemic Attack, Transmissible Spongiform Encephalopathies, Transverse Myelitis, Traumatic Brain Injury, Tremor, Trigeminal Neuralgia, Tropical

Spastic Paraparesis, Troyer Syndrome, Tuberous Sclerosis, Vascular Erectile Tumor, Vasculitis Syndromes of the Central and Peripheral Nervous Systems, Von Economo's Disease, Von Hippel-Lindau Disease (VHL), Von Recklinghausen's Disease, Wallenberg's Syndrome, Werdnig-Hoffman Disease, Wernicke-Korsakoff Syndrome, West Syndrome, Whiplash, Whipple's Disease, Williams Syndrome, Wilson's Disease, Wolman's Disease, X-Linked Spinal and Bulbar Muscular Atrophy, Zellweger Syndrome, optic neuritis, Chronic fatigue syndrome, fibromialgia, psychiatric diseases such as mood disorders, major depression, bipolar syndrome, psychosis, schizophrenia, obsessive-compulsive-syndrome, etc., Toxic or drug abuse diseases such as alcoholism and drug abuse, Encephalopathy like hepatic encephalopathy.

Psychiatric disorders, which may be the subject of prevention and/or treatment according to the present invention include those listed by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) published by the American Psychiatric Association, and covers all mental health disorders for both children and adults. In particular, psychiatric disorders include a disorder selected from Acute Stress Disorder; Adjustment Disorder Unspecified; Adjustment Disorder with Anxiety; Adjustment Disorder with Depressed Mood; Adjustment Disorder with Disturbance of Conduct; Adjustment Disorder with Mixed Anxiety and Depressed Mood; Adjustment Disorder with Mixed Disturbance of Emotions and Conduct; Agoraphobia without History of Panic Disorder; Anorexia Nervosa; Antisocial Personality Disorder; Anxiety Disorder Due to Medical Condition; Anxiety Disorder, NOS; Avoidant Personality Disorder; Bipolar Disorder NOS; Bipolar I Disorder, Most Recent Episode Depressed, In Full Remission; Bipolar I Disorder, Most Recent Episode Depressed, In Partial Remission; Bipolar I Disorder, Most Recent Episode Depressed, Mild; Bipolar I Disorder, Most Recent Episode Depressed, Moderate; Bipolar I Disorder, Most Recent Episode Depressed, Severe With Psychotic Features; Bipolar I Disorder, Most Recent Episode Depressed, Severe Without Psychotic Features; Bipolar I Disorder, Most Recent Episode Depressed, Unspecified; Bipolar I Disorder, Most Recent Episode Manic, In Full Remission; Bipolar I Disorder, Most Recent Episode Manic, In Partial Remission; Bipolar I Disorder, Most Recent Episode

Manic, Mild; Bipolar I Disorder, Most Recent Episode Manic, Moderate; Bipolar I Disorder, Most Recent Episode Manic, Severe With Psychotic Features; Bipolar I Disorder, Most Recent Episode Manic, Severe Without Psychotic Features; Bipolar I Disorder, Most Recent Episode Manic, Unspecified; Bipolar I Disorder, Most Recent Episode Mixed, In Full Remission; Bipolar I Disorder, Most Recent Episode Mixed, In Partial Remission; Bipolar I Disorder, Most Recent Episode Mixed, Mild; Bipolar I Disorder, Most Recent Episode Mixed, Moderate; Bipolar I Disorder, Most Recent Episode Mixed, Severe With Psychotic Features; Bipolar I Disorder, Most Recent Episode Mixed, Severe Without Psychotic Features; Bipolar I Disorder, Most Recent Episode Mixed, Unspecified; Bipolar I Disorder, Most Recent Episode Unspecified; Bipolar I Disorder, Most Recent Episode Hypomanic; Bipolar I Disorder, Single Manic Episode, In Full Remission; Bipolar I Disorder, Single Manic Episode, In Partial Remission; Bipolar I Disorder, Single Manic Episode, Mild; Bipolar I Disorder, Single Manic Episode, Moderate; Bipolar I Disorder, Single Manic Episode, Severe With Psychotic Features; Bipolar I Disorder, Single Manic Episode, Severe Without Psychotic Features; Bipolar I Disorder, Single Manic Episode, Unspecified; Bipolar II Disorder; Body Dysmorphic Disorder; Borderline Personality Disorder; Breathing-Related Sleep Disorder; Brief Psychotic Disorder; Bulimia Nervosa; Circadian Rhythm Sleep Disorder; Conversion Disorder; Cyclothymic Disorder; Delusional Disorder; Dependent Personality Disorder; Depersonalization Disorder; Depressive Disorder NOS; Dissociative Amnesia; Dissociative Disorder NOS; Dissociative Fugue; Dissociative Identity Disorder; Dyspareunia; Dyssomnia NOS; Dyssomnia Related to (Another Disorder); Dysthymic Disorder; Eating Disorder NOS; Exhibitionism; Female Dyspareunia Due to Medical Condition; Female Hypoactive Sexual Desire Disorder Due to Medical Condition; Female Orgasmic Disorder; Female Sexual Arousal Disorder; Fetishism; Frotteurism; Gender Identity Disorder in Adolescents or Adults; Gender Identity Disorder in Children; Gender Identity Disorder NOS; Generalized Anxiety Disorder; Histrionic Personality Disorder; Hypoactive Sexual Desire Disorder; Hypochondriasis; Impulse -Control Disorder NOS; Insomnia Related to Another Disorder; Intermittent Explosive Disorder; Kleptomania; Major Depressive Disorder, Recurrent, In Full Remission; Major Depressive Disorder, Recurrent, In Partial Remission; Major Depressive

Disorder, Recurrent, Mild; Major Depressive Disorder, Recurrent, Moderate; Major Depressive Disorder, Recurrent, Severe With Psychotic Features; Major Depressive Disorder, Recurrent, Severe Without Psychotic Features; Major Depressive Disorder, Recurrent, Unspecified; Major Depressive Disorder, Single Episode, In Full
5 Remission; Major Depressive Disorder, Single Episode, In Partial Remission; Major Depressive Disorder, Single Episode, Mild; Major Depressive Disorder, Single Episode, Moderate; Major Depressive Disorder, Single Episode, Severe With Psychotic Features; Major Depressive Disorder, Single Episode, Severe Without Psychotic Features; Major Depressive Disorder, Single Episode, Unspecified; Male
10 Dyspareunia Due to Medical Condition; Male Erectile Disorder; Male Erectile Disorder Due to Medical Condition; Male Hypoactive Sexual Desire Disorder Due to Medical Condition; Male Orgasmic Disorder; Mood Disorder Due to Medical Condition; Narcissistic Personality Disorder; Narcolepsy; Nightmare Disorder; Obsessive Compulsive Disorder; Obsessive-Compulsive Personality Disorder; Other
15 Female Sexual Dysfunction Due to Medical Condition; Other Male Sexual Dysfunction Due to Medical Condition; Pain Disorder Associated with both Psychological Factors and Medical Conditions; Pain Disorder Associated with Psychological Features; Panic Disorder with Agoraphobia; Panic Disorder without Agoraphobia; Paranoid Personality Disorder; Paraphilia, NOS; Parasomnia NOS;
20 Pathological Gambling; Pedophilia; Personality Disorder NOS; Posttraumatic Stress Disorder; Premature Ejaculation; Primary Hypersomnia; Primary Insomnia; Psychotic Disorder Due to Medical Condition, with Delusions; Psychotic Disorder Due to Medical Condition, with Hallucinations; Psychotic Disorder, NOS; Pyromania; Schizoaffective Disorder; Schizoid Personality Disorder; Schizophrenia, Catatonic
25 Type; Schizophrenia, Disorganized Type; Schizophrenia, Paranoid Type; Schizophrenia, Residual Type; Schizophrenia, Undifferentiated Type; Schizophreniform Disorder; Schizotypal Personality Disorder; Sexual Aversion Disorder; Sexual Disorder NOS; Sexual Dysfunction NOS; Sexual Masochism; Sexual Sadism; Shared Psychotic Disorder; Sleep Disorder Due to A Medical
30 Condition, Hypersomnia Type; Sleep Disorder Due to A Medical Condition, Insomnia Type; Sleep Disorder Due to A Medical Condition, Mixed Type; Sleep Disorder Due to A Medical Condition, Parasomnia Type; Sleep Terror Disorder; Sleepwalking

Disorder; Social Phobia; Somatization Disorder; Somatoform Disorder NOS; Specific Phobia; Transvestic Fetishism; Trichotillomania; Undifferentiated Somatoform Disorder; Vaginismus; and Voyeurism.

5 Preferably, the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, can be used in the treatment of diseases wherein NGF has been proven effective in the state of the art, either in vivo or in vitro, due to their improving effects on cell differentiation and cell survival, through TrkA pathway. Therefore, the compounds covered in the present invention can be used in the
10 treatment of neurological diseases selected among: neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Friedreich's ataxia, Huntington's disease, Dementia with Lewy bodies, spinal muscular atrophy; nerve inflammation, such as multiple sclerosis and neuromyelitis optica, major depressive disorder, schizophrenia, glaucoma; or peripheral
15 neuropathies, such as diabetic or AIDS neuropathy. Moreover, the compounds of the invention can also be indicated for treatment of cancer, by modulating NGF cell differentiation activity and stopping cell proliferation. Among the cancer types in which NGF has been proven effective in the state of the art, either in vivo or in vitro, due to improving effects on cell differentiation and cell survival, through either TrkA
20 and/or p75 pathways, the following may be cited: glioblastoma, astrocytoma, meduloblastoma, neurinoma, neuroblastoma, meningioma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, leukemia, acute lymphocytic leukemia, osteosarcoma, hepatocellular carcinoma, ovarian carcinoma, lung adenocarcinoma or esophagic carcinoma.

25

In one embodiment of the present invention, in the various uses and methods of neuroprotection or of prevention or treatment of nerve cell death or damage, the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, are administered to a healthy subject, preferably a healthy subject
30 older than 18 years old, more preferably a healthy subject older than 45 years old, even more preferably a healthy subject older than 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 years old.

The term “healthy subject” is meant to comprise its plain meaning as well as those subjects that may suffer from one or more pathological conditions other than a neurological or psychiatric disease.

5

The neuroprotective properties of the compounds of any of Formulae I-IV, and pharmaceutically salts and/or prodrugs thereof, have as a consequence the partial or full prevention or treatment of the various disorders in the nervous system functions caused by the neuronal cell death or damage. Therefore, the present invention further relates to the use of the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, as active ingredients in the manufacture of a medicament for the prevention or treatment of a neurological or psychiatric disease. In other words, the present invention also relates to the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, for use in the prevention or treatment of a neurological or psychiatric disease. Similarly, the present invention also relates to a method of prevention or treatment of a neurological or psychiatric disease comprising administering to a subject in need thereof an effective amount of the compounds of any of Formulae I-IV, or a pharmaceutically acceptable salt and/or prodrug thereof. The neurological or psychiatric disease may be any one from those listed above.

Preferably, the disease treated or prevented with the administration of the compounds of the invention is selected from: neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Alzheimer’s disease, Friedreich’s ataxia, Huntington’s disease, Dementia with Lewy bodies, spinal muscular atrophy; inflammation, such as multiple sclerosis and neuromyelitis optica, major depressive disorder, schizophrenia, glaucoma; peripheral neuropathies, such as diabetic or AIDS neuropathy; and cancer, such as glioblastoma, astrocytoma, medulloblastoma, neurinoma, neuroblastoma, meningioma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, leukemia, acute lymphocytic leukemia, osteosarcoma, hepatocellular carcinoma, ovarian carcinoma, lung adenocarcinoma, and esophagic carcinoma.

Another goal of the present invention is the use of the compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, as neuroenhancing drugs or the use for manufacturing neuroenhancing drugs.

5

Neuroenhancing drugs include those that improve learning and memory, attention, mood, communicative skills and sexual performance. Examples of neuroenhancing drugs are those that target long-term synaptic potentiation (LTP) or long-term depression (LTD), modulation of calcium channels, or the cAMP response element-binding (CREB) protein. cAMP is the acronym for cyclic adenosine monophosphate. Particular examples of neuroenhancing drugs are phosphodiesterase inhibitors like rolipram; donepezil; agonists of the NMDA glutamate receptor like D-cycloserine; ampakines; modafinil; methylphenidate.

10

15 The compounds of any of Formulae I-IV, and pharmaceutically acceptable salts and/or prodrugs thereof, may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs, for example any solid (e.g. tablets, capsules, granules, etc.) or liquid composition (e.g. solutions, 20 suspensions, emulsions, etc). To prepare the pharmaceutical compositions of the compounds of any of Formulae I-IV, an effective amount of the compound of any of Formulae I-IV, optionally in salt form or a prodrug, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired 25 for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, intrathecal, intravenous or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case 30 of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets.

Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier usually comprises sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent or a suitable wetting agent, or both, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. A review of the different pharmaceutical forms for drug administration and their preparation may be found in the book "Tratado de Farmacia Galénica", de C. Faulí i Trillo, 10th Edition, 1993, Luzán 5, S.A. de Ediciones.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.

The compositions in accordance with this invention, including unit dosage forms, may contain the active ingredient in an amount that is in the range of about 0,1 % to 70%, or about 0,5% to 50%, or about 1 % to 25%, or about 5% to 20%, the remainder comprising the carrier, wherein the foregoing percentages are w/w versus the total weight of the composition or dosage form.

The dose of the compound of any of Formulae I-IV, its pharmaceutically acceptable salt and/or prodrug thereof, to be administered depends on the individual case and, as customary, is to be adapted to the conditions of the individual case for an optimum effect. Thus it depends, of course, on the frequency of administration and on the potency and duration of action of the compound employed in each case for therapy or prophylaxis, but also on the nature and severity of the disease and symptoms, and on the sex, age, weight co-medication and individual responsiveness of the subject to be treated and on whether the therapy is acute or prophylactic. Doses may be adapted in function of weight and for pediatric applications. Daily doses may be administered q.d. or in multiple quantities such as b.i.d., t.i.d. or q.i.d.

Synthesis of Compounds

The compounds of the present invention can be prepared using methods known to those skilled in the art in view of this disclosure. For example, compounds of the present invention can be prepared as described in Masip, *et al.*, 2004.

Testing of Compounds

In addition to the tests described in the Examples, the compounds of the present invention can be tested in *in vitro* model for Parkinson's disease as follows: The human neuroblastoma cell line SH-SY5Y is used to study the neuroprotective effect of the tested molecules in Parkinson disease. The cells are pre-treated for 3 hours with the tested molecules at different concentrations (20 ng/ml, 100 ng/ml, 2 µg/ml, 20 µg/ml and 50 µg/ml) with the tested molecules (100ng/ml). Then 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (100 µM) is added and incubated for 24 hrs. The number of surviving cells is determined the day after by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

The compounds of the present invention can also tested in an Alzheimer disease *in vitro* model as follows: The human neuroblastoma cell line SH-SY5Y is used to study the neuroprotective effect of the tested compound in Alzheimer disease. The cells are pre-treated for 3 hours with the tested compound at different concentrations (20 ng/ml, 100 ng/ml, 2 µg/ml, 20 µg/ml and 50 µg/ml) with the tested compound (100 ng/ml).

Then Amiloid beta fibrils (100 μ M) is added and incubated for 24 hrs. The number of surviving cells is determined the day after by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

- 5 Further, the compounds of the present invention can be tested in a glaucoma model as follows: 12 Sprague Dawley rats (4 months of age) are anesthetized with isobutane and subjected to hypertonic saline solution injection into the episcleral vein of the right eye. Intraocular pressure is measured before the operation and is monitored one time a week using a TonoLab for 7 weeks. Treatment with the tested molecules
10 begins one week after glaucoma induction by topical application at the conjunctive. The test molecule is dissolved into physiological solution and is used at two different concentration (200 μ g/ml and 400 μ g/ml). NGF is used as positive control (200 μ g/ml) and the physiological solution, used to dissolve all the molecules, is subministered as placebo. The animals are divided into 4 groups (3 animals in each
15 group): glaucoma-test molecule 200 μ g/ml; glaucoma-test molecule 400 μ g/ml; glaucoma-NGF; glaucoma-placebo. Three animals are used as control without glaucoma. Seven weeks after glaucoma induction, animals are sacrificed by overdose of anaesthetic and their eyes are taken and fixed in 4% of PFA. The eyes are included in paraffin and cut into 20 μ m sections to be used for histological studies
20 (hematoxilin-eosin staining). The cell count of the number of retinal ganglion cells (RGC) is performed randomly in ten different fields for each eye.

- The following examples are illustrative, but not limiting, of the compounds, compositions and methods of the present invention. Suitable modifications and
25 adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art in view of this disclosure are within the spirit and scope of the invention.

Examples

30

EXAMPLE 1

Design of NGF agonists by combinatorial chemistry

General. Solvents, amines and other reagents were purchased from commercial


suppliers and used without further purification. Reaction carried out under microwave irradiation were conducted in a 100 mL round bottomed flask equipped with a Dimroth condenser. The flask was introduced in the monomode cavity of a CEM Model Discover apparatus. The NMR spectra were recorded on a Varian Inova 500
5 apparatus (^1H NMR, 500 MHz; ^{13}C NMR, 125 MHz) and on a Unity 300 apparatus (^1H NMR, 300 MHz; ^{13}C NMR, 75 MHz). When appropriate, the assignment of ^1H and ^{13}C NMR peaks for compounds were confirmed by gDQCOSY and gHSQC experiments. The occurrence of different conformers led to highly complex spectra; the absorptions given below are referred to the major conformer present in the sample.

10 The RP-HPLC analyses were performed with a Hewlett Packard Series 1100 (UV detector 1315A) modular system using a reverse-phase Kromasil 100 C8 (25 x 0.46 cm, 5 μm) column, with CH_3CN -buffer ammonium formate (20 mM, pH=5.0) mixtures at 1 mL/min as mobile phase and monitoring at 220 nm. Semi-preparative RP-HPLC was performed with a Waters (Milford, MA, U.S.A.) system. High
15 resolution mass spectra (HRMS-FAB) were carried at the Mass Spectrometry Service of the IQAC – Instituto de Química Avanzada de Cataluña – (Spain).

Library of tetraalkylammonium derivatives. This library of discrete compounds was designed and constructed as previously reported (Masip et al., 2004).

Preparation of individual 3-oxopiperazinium derivatives for the in vivo
20 **assays.**

Scheme 1. Solution-Phase Synthesis of 3-Oxopiperazinium Derivatives.^a



^aReagents and conditions: (a) HOOCCH_2Cl , DIC, HOBT, DIPEA, DCM; (b) $\text{H}_2\text{NCH}_2\text{CH}_2\text{R}^1\text{R}^2$, DIPEA, dioxane; (c) ClCOCH_2Cl , DCM; (d) Al_2O_3 , DCM-MeOH (2:1).

- 5 The individual tetraalkylammonium salts A26-23 and A26-64 for the in vivo assays were prepared similarly to the corresponding library, but improving each step in order to achieve the highest yields and purities. In the case of A26-64, it was necessary to prepare *N*-benzyl-*N*-methylethane-1,2-diamine. This compound was obtained from the corresponding alcohol precursor by the Mitsunobu procedure,
- 10 followed by hydrazinolysis. (Sen, S. et al, 1995).

Synthesis of *N*-benzyl-*N*-methylethane-1,2-diamine. To a solution of *N*-benzyl-*N*-methylethanolamine (7.31 mL, 40.5 mmol), phthalimide (6.62 g, 44.5 mmol), and triphenyl phosphine (14 g, 52.65 mmol) in anhydrous THF (240 mL), cooled at 0 °C, diisopropyl diazacarboxylate (12.73 mL, 60.75 mmol) was added dropwise in the

15 absence of light. The mixture was stirred for 15 h at 20°C and then the solvent was removed under reduced pressure. The expected phthalimide derivative was isolated in 80% yield (70% purity) after repeated treatment with 1:1 AcOEt:Et₂O mixtures to remove Ph_3P and Ph_3PO by precipitation. The phthalimide derivative (16.8 g, 39 mmol) was redissolved in absolute ethanol (200 mL) treated with hydrazine hydrate (9.7 mL,

20 195 mmol), and the mixture was stirred for 6 h at 80 °C. The crude reaction mixture

was acidified with 1.5 N HCl and the resulting suspension was filtered. The solvents were removed under reduced pressure, the residue was redissolved in CH₂Cl₂ and the amine was extracted with 1.5 N HCl. This acid solution was taken to pH with NaOH and extracted with CH₂Cl₂. The combined organic fractions were washed (brine),
5 dried (MgSO₄) and concentrated in vacuo. The *N*-benzyl-*N*-methylethane-1,2-diamine was purified by vacuum distillation as a colorless oil (4.3 g, 88% yield, 95% purity). ¹H NMR (300 MHz, CDCl₃) δ 7.3-7.2 (ca, 5H, H_{Ar}), 3.50 (s, 2H, NCH₂Ph), 2.79 (t, ³J_{HH}=6 Hz, 2H, CH₂NH₂), 2.45 (t, ³J_{HH}=6 Hz, 2H, CH₂N), 2.20 (s, 3H, CH₃N), 1.62 (NH₂); ¹³C NMR (75 MHz, CDCl₃) δ 128.9 (CH_{Ar}, 2,6-CH), 128.2 (CH_{Ar}, 3,5-CH), 126.9 (CH_{Ar}, 4-CH), 62.6 (NCH₂Ph), 60.0 (CH₂N), 42.1 (CH₃N), 39.5 (CH₂NH₂); HRMS calcd for C₁₀H₁₆N₂ 165.1392 (M + H)⁺, found 165.1390.

Synthesis of *N*-(4-nitrophenethyl)-2-chloroacetamide. A suspension of 2-(4-nitrophenyl)ethylamine hydrochloride (3.5 g, 17 mmol) in 30 mL anhydrous CH₂Cl₂ was stirred with *N,N*-diisopropylethylamine (2.94 mL, 17 mmol). Chloroacetic acid
15 (1.60 g mmol, 17.0 mmol) in 10 mL anhydride DCM was added dropwise to the stirred solution containing the free amine maintained at 0 °C and under argon atmosphere, followed by the addition of (*N,N'*-diisopropylcarbodiimide, 2.93 mL, 18.7 mmol) and 1-hydroxybenzotriazole hydrate (2.3 g, 18.7 mmol). Then, the mixture was stirred for 2 h at 20 °C. The crude reaction mixture was cooled at 0 °C, filtered and washed with
20 2 N HCl, brine and dried. Elimination of solvent yielded the expected *N*-substituted chloroacetamide (7.4 g, 90% yield, 95% purity). ¹H NMR (300 MHz, CDCl₃) δ 8.18 (d, ³J_{HH}=8.5 Hz, 2H, 3,5-H C₆H₄NO₂), 7.37 (d, ³J_{HH}=8.5 Hz, 2H, 2,6-H C₆H₄NO₂), 6.64 (s, 1H, NH), 4.04 (s, 2H, COCH₂Cl), 3.61 (q, ³J_{HH}=7 Hz, 2H, CH₂NH), 2.97 (t, ³J_{HH}=7 Hz, 2H, CH₂CH₂NH); ¹³C NMR (75 MHz, CDCl₃) δ 165.3 (NHCO), 146.9 (1,4-C C₆H₄NO₂), 129.6 (2,6-CH C₆H₄NO₂), 123.9 (3,5-CH C₆H₄NO₂), 43.5 (CH₂Cl), 40.8 (CH₂NH), 35.4 (CH₂CH₂NH).

Preparation of 1,1-dimethyl-4-[2-(4-nitrophenethylamino)-2-oxoethyl]-3-oxopiperazinium chloride (A26-23).

Coupling of N,N'-dimethylethylenediamine. A mixture of the *N*-substituted
30 chloroacetamide (2.97 g, 11.6 mmol), *N,N'*-dimethylethylenediamine (7.1 mL, 62

mmol) and *N,N*-diisopropylethylamine (4.3 mL, 24.7 mmol) in dioxane (25 mL) was allowed to react under microwave irradiation with the CEM reactor equipped with a Dimroth condenser (10 min, 80 °C, 150 W). Then the solvent was removed under reduced pressure to give the corresponding glycineamide (5.05 g crude, 98% yield, 71% purity by HPLC). ¹H NMR (400 MHz, (CD₃)₂O) δ 8.17 (d, ³J_{HH}=8.5 Hz, 2H, 3,5-H C₆H₄NO₂), 7.57 (d, ³J_{HH}=8.5 Hz, 2H, 2,6-H C₆H₄NO₂), 3.43 (q, ³J_{HH}=7 Hz, 2H, CH₂CH₂NH), 3.15 (s, 2H, COCH₂NH), 3.03 (t, ³J_{HH}=7 Hz, 2H, CH₂CH₂NH), 2.76 (t, ³J_{HH}=7 Hz, 2H, NHCH₂CH₂N), 2.48 (s, 6H, 2 x CH₃N), 2.25 (t, ³J_{HH}=7 Hz, 2H, NHCH₂CH₂N); ¹³C NMR (75 MHz, CDCl₃) δ 165.3 (NHCO), 146.9 (1,4-C₆H₄NO₂), 129.6 (2,6-CH C₆H₄NO₂), 123.8 (3,5-CH C₆H₄NO₂), 58.8 (CH₂CH₂N), 52.6 (COCH₂NH), 47.4 (CH₂CH₂N), 45.5 (2 x CH₃N), 39.7 (CH₂CH₂NH), 35.8 (CH₂CH₂NH). Underlined atoms are the ones responsible of RMN signals detected herein.

Acylation of the glycineamide and final cyclization. Chloroacetyl chloride (1.41 mL, 17.75 mmol) was added to a stirred suspension of the glycineamide intermediate (5.0 g, 12.07 mmol) in anhydrous CH₂Cl₂ (20 mL) at 0 °C, and the mixture was stirred for 1 h, filtered and evaporated to dryness (7.4 g crude, 57% purity). The residue was redissolved in a 2:1 mixture of DCM/MeOH (50 mL), and the solution was treated with basic aluminum oxide (20 % w/w) for 15 h at 20 °C. The crude reaction mixture was filtered, and the solvent was removed to give the expected product as solid. The compound was washed by using subsequent mixtures of solvents to yield 1.6 g of the cyclic tetraalkylammonium compound (36% overall yield from starting amine, 95% purity). ¹H NMR (500 MHz, D₂O) δ 8.17 (d, ³J_{HH}=8.5 Hz, 2H, 3,5-H C₆H₄NO₂), 7.46 (d, ³J_{HH}=8.5 Hz, 2H, 2,6-H C₆H₄NO₂), 4.22 (s, 2H, COCH₂N⁺), 4.11 (s, 2H, COCH₂N), 3.84 (t, ³J_{HH}=6 Hz, 2H, NCH₂CH₂N⁺), 3.72 (t, ³J_{HH}=6 Hz, 2H, NCH₂CH₂N⁺), 3.55 (t, ³J_{HH}=7 Hz, 2H, CH₂CH₂NH), 3.31 (s, 6H, 2 x CH₃N⁺), 2.95 (t, ³J_{HH}=7 Hz, 2H, CH₂CH₂NH); ¹³C NMR (100 MHz, D₂O) δ 168.9 (NHCO), 162.4 (NCO), 147.8 (1-C C₆H₄NO₂), 146.5 (4-C C₆H₄NO₂), 130.1 (2,6-CH C₆H₄NO₂), 123.8 (3,5-CH C₆H₄NO₂), 57.3 (COCH₂N⁺), 52.5 (2 x CH₃N⁺), 49.0 (CH₂CH₂N⁺), 42.9 (COCH₂N), 40.2 (CH₂CH₂N⁺), 35.8 (C_{Ar}CH₂CH₂), 34.8 (C_{Ar}CH₂CH₂); HRMS calcd for C₁₆H₂₃N₄O₄⁺ 335.1714 (M)⁺, found 335.1714.

Preparation of 1-benzyl-1-methyl-4-[2-(4-nitrophenethylamino)-2-oxoethyl]-3-oxopiperazinium chloride (A26-64).


Coupling of N-benzyl-¹-methylethane-1,2-diamine. To a solution of the *N*-substituted chloroacetamide (1,01 g, 3.95 mmol) in anhydrous dioxane (20 mL), it was added *N*-benzyl-*N*-methylethane-1,2-diamine (0.64 mL, 4.2 mmol), anhydrous CsCO₃ (14 g, 43 mmol) and activated molecular sieves (Type A4). The mixture was allowed to react under microwave irradiation for 2 h by subsequent cycles of 10 min at 90 °C (150 W). The crude reaction mixture was filtered and the solid was washed with dioxane. Final product was isolated after elimination of solvent under vacuum (3.52 g, 77% yield, 60% purity). ¹H NMR (500 MHz, (CDCl₃) δ 8.16 (d, ³*J*_{HH} = 8.5 Hz, 2H, 3,5-H C₆H₄NO₂), 7.56 (t, ³*J*_{HH} = 7.5 Hz, 1H, 4-H C₆H₅), 7.34 (d, ³*J*_{HH} = 8.5 Hz, 2H, 2,6-H C₆H₄NO₂), 7.32-7.27 (4H, 2,3,5,6-H C₆H₅), 3.71 (s, 2H, NCH₂Ph), 3.55 (q, ³*J*_{HH} = 7 Hz, 2H, CH₂CH₂NH), 3.18 (s, 2H, COCH₂NH), 2.93 (t, ³*J*_{HH} = 7 Hz, 2H, CH₂CH₂NH), 2.58 (t, ³*J*_{HH} = 5.5 Hz, 2H, NHCH₂CH₂N), 2.41 (t, ³*J*_{HH} = 5.5 Hz, 2H, NHCH₂CH₂N), 2.18 (s, 3H, CH₃N).

Acylation of the glycinamide and final cyclization. Acylation of this glycinamide was carried out as described for A26-23 to give 3.82 g of the crude product (88% yield, 58% purity). This crude was redissolved in 30 mL of a 2:1 DCM:MeOH mixture and treated with basic aluminum oxide (20 % w/w). The cyclization was performed under microwave activation for 20 min (30 °C, 150 W). The crude reaction mixture was filtered and concentrated under vacuum to give the expected product as a solid. Purification was accomplished by extractions and reprecipitation in different solvents. Finally, 1.57 g, of the cyclic tetraalkylammonium compound were isolated (80% overall yield from starting amine, 95% purity). ¹H NMR (500 MHz, D₂O) δ 8.16 (d, ³*J*_{HH}=8.5 Hz, 2H, 3,5-H C₆H₄NO₂), 7.62 (tt, ³*J*_{HH}=7.5 Hz, ⁴*J*_{HH}=2.5 Hz, 1H, 4-H C₆H₅), 7.57 (tt, ³*J*_{HH}=7.5 Hz, 2H, 3,5-H C₆H₅), 7.54 (tt, ³*J*_{HH}=7.5 Hz, 2H, 2,6-H C₆H₅), 7.45 (d, ³*J*_{HH}=8.5 Hz, 2H, 2,6-H C₆H₄NO₂), 4.73 (d, ²*J*_{HH}=13 Hz, 1H, NCH_{a,b}Ph), 4.65 (d, ²*J*_{HH}=13 Hz, 1H, NCH_{a,b}Ph), 4.26 (d, ²*J*_{HH}=16.5 Hz, 1H, COCH_{a,b}N⁺), 4.06 (d, ²*J*_{HH}=16.5 Hz, 1H, COCH_{a,b}N⁺), 4.10 (d, ²*J*_{HH}=3 Hz, 2H, COCH₂N), 3.82-3.7 (4H, NCH₂CH₂N⁺ + NCH₂CH₂N⁺), 3.54 (t, ³*J*_{HH}=6.5 Hz, 2H, CH₂CH₂NH), 3.18 (s, 3H, CH₃N⁺), 2.94 (t, ³*J*_{HH}=6.5 Hz, 2H, CH₂CH₂NH); ¹³C NMR

(100 MHz, D₂O) δ 168.8 (NHCO), 162.5 (NCO), 147.8 (1-C C₆H₄NO₂), 146.4 (4-C C₆H₄NO₂), 133.1 (2,6-CH C₆H₅), 131.4 (1-CH C₆H₅), 130.1 (2,6-CH C₆H₄NO₂), 129.5 (3,5-CH C₆H₅), 125.6 (4-C C₆H₅), 123.7 (3,5-CH C₆H₄NO₂), 69.0 (COCH₂N⁺), 59.6 (CH₂ C₆H₅), 54.8 (COCH₂N), 48.9 (CH₃N⁺), 47.9 (CH₂CH₂N⁺), 42.6 (CH₂CH₂N⁺), 40.1 (C_{Ar}CH₂CH₂), 34.8 (C_{Ar}CH₂CH₂); HRMS calcd for C₂₂H₂₇N₄O₄⁺ 411.2027 (M)⁺, found 411.2028.

Preparation of 3-oxopiperazinium derivative A28-6 for the in vitro assays.

Scheme 2. Solution-Phase Synthesis of 3-Oxopiperazinium Derivative A28-6.^a



^a Reagents and conditions: (a) ClCOCH₂Cl, K₂CO₃, CH₂Cl₂, 0 °C, 30 min; (b) Wang aldehyde resin (3.5 equivalents/equivalents amine), dioxane, microwave irradiation, 40 min; (c) 2-(pyrrolidin-1-yl)ethanamine (3 equivalents), K₂CO₃ (3 equivalents), dioxane, 90 °C, 3h; (d) Wang aldehyde resin (3 equivalents/equivalents amine), dioxane, microwave irradiation, 20 min; (e) ClCOCH₂Cl (1 equivalents), K₂CO₃ (3 equivalents), CH₂Cl₂, 0 °C, 30 min; (f) Al₂O₃, CH₂Cl₂-MeOH (2:1).

Synthesis of 8-[2-(2-(5-methyl-1*H*-indol-2-yl)ethylamino)-2-oxoethyl]-7-oxo-8-aza-5-azoniaspiro[4.5]decane. (A28-A6). The individual tetraalkylammonium salt A28-A6 was obtained from the preparation of the library of tetraalkylammonium derivatives. The synthetic procedure involved a 6-step sequence carried out in solution, along with the use of solid-phase linked scavengers and microwave activation for the rapid removal of the excess of amine reagents.

Synthesis of N-(5-methyltryptamine)-2-chloroacetamide. Chloroacetyl chloride (16 μ L, 0.2 mmol) was added dropwise to a stirred suspension of 5-methyltryptamine (52.3 mg, 0.3 mmol, 1.5 equivalents) and K_2CO_3 (55.3 mg, 0.4 mmol) in anhydrous CH_2Cl_2 maintained at 0 $^{\circ}C$. The mixture was stirred at this temperature for 30 min, filtered and evaporated to render a residue which was redissolved in dioxane (0.5 mL) and treated with the 4-benzyloxybenzaldehyde polystyrene resin (Wang aldehyde HL) (0.35 mmol, 3.5 equivalents relative to the amine, 2.8 mmol/g). The reaction mixture was placed in a domestic microwave and irradiated (350 W) for 40 min at 4-min intervals. The crude reaction mixture was filtered, and the resin was washed with dioxane (2 mL) and CH_2Cl_2 (3 x 2 mL). The filtrate was evaporated to afford the corresponding *N*-substituted chloroacetamide.

Coupling of the 2-(pyrrolidin-1-yl)ethanamine (A6). The residue obtained was dissolved in dioxane (2 mL) and treated with the 2-(pyrrolidin-1-yl)ethanamine (76 μ L, 0.6 mmol) and K_2CO_3 (55.3 mg, 0.4 mmol). The mixture was stirred at 90 $^{\circ}C$ for 3 h, filtered, and concentrated to 1 mL. This solution was treated with the Wang aldehyde HL resin (1.2 mmol, 3 equivalents relative to the amine, 2.8 mmol/g) for 20 min in the microwave oven (4-min intervals). The resin was filtered and washed with dioxane (2 mL) and CH_2Cl_2 (3 x 2 mL). The filtrate was evaporated to obtain the glycineamide.

Acylation of the glycineamide. Chloroacetyl chloride (16 μ L, 0.2 mmol) was added to a stirred suspension of the glycineamide and K_2CO_3 (55.3 mg, 0.4 mmol) in CH_2Cl_2 (2.5 mL) at 0 $^{\circ}C$, and the mixture was stirred for 30 min, filtered and evaporated to dryness.

Cyclization. The former residue was redissolved in a 2:1 mixture of CH_2Cl_2 /MeOH (2 mL), and the solution was treated with basic aluminum oxide for 1 h at 20 $^{\circ}C$. The crude reaction mixture was filtered, and the solvent was removed to give the corresponding cyclic tetraalkylammonium compound (57% overall yield from starting amine, 65% purity determined by HPLC-UV). The compound was identified by HPLC-MS.

EXAMPLE 2

PC12 cell differentiation**A26-23, A26-24 and A28-A6 peptidomimetics induce neuronal differentiation.**

PC 12 cell differentiation was measured by plating cells onto collagen-coated 24-wells
5 plates. NGF (100 ng/ml) or the small chemicals at different concentrations were added
and the percentage of cells with neurite processes greater than two cell bodies in
length were counted after relevant treatment. For each experiment at least 300 cells
were randomly measured (Burstein and Greene, 1978).

10 *Cell culture.* PC12 cells were maintained at 37°C in DMEM supplemented with 2.5%
FBS, 15% of Horse serum (HS) and penicillin/streptomycin in a humidified 5% CO₂
incubator. The cells were grown on 60-and 100-mm tissue culture dishes (Becton
Dickinson).

15 PC 12 cells were cultured for 3 days in the presence of the peptoids (from 2 ng/ml to
50 µg/ml) under reduced serum conditions (0.5% FBS and 1% HS). The peptoids
A26-23, A26-24 and A28-A6 (FIG. 1) were found to induce the differentiation of
PC12 cells at different concentrations to an extent substantially comparable with that
induce by NGF (Foehr et al., 2000) and showing a dose-response activity.

20

EXAMPLE 3

Survival assays**A26-23, A26-24 and A28-A6 mimetic peptoids do not promote myelin cells survival via p75 receptor.**

25 Compounds identified from the initial library screening were also tested to assess their
capacity to promote cell survival of myelin producing cells. To delineate p75
signalling independent of TrkA, we used a rat schwannoma cell line (RN22)
expressing p75, but not TrkA, (Gentry et al., 2000).

30 *Cell culture.* The rat schawnnoma cell line RN22 was cultured in 5% CO₂ at 37°C in
Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS)
and penicillin/streptomycin.

RN22 cells were plated at 20,000 cells/well on a 24-well plate in DMEM alone and after allowing the cells to adhere for 3 days, copper sulphate (CuSO₄) (150 µM) was added with or without NGF (100 ng/ml) or the peptidomimetic molecules A26-23, A26-24 and A28-A6 at different concentrations (1 ng/ml – 10 µg/ml) to generate stress and cell death. After 24 h cell viability was studied by determining the amount of yellow MTT (Sigma) that was reduced to insoluble purple formazan. After removing the medium, the water-insoluble formazan was solubilised with DMSO (Sigma), and the dissolved material was measured spectrophotometrically at a wavelength of 570 nm, subtracting the background at 650 nm (Frade, 2005).

After 24 h, cell viability was tested and peptidomimetic compounds A26-23, A26-24 and A28-A6 were found not to promote survival of RN22 cells at different concentrations (FIG. 2), hence indicating that the effects of these peptidomimetics are not exerted via p75 receptor.

Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof.

Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

All patents and publications cited herein are fully incorporated by reference herein in their entirety.

References

Aloe L, Calzá L (2004) Progress in brain research. Vol 146, NGF and related molecules in health and diseases. Amsterdam: Elsevier.

Anand P. Neurotrophic factors and their receptors in human sensory neuropathies. *Prog Brain Res.* 2004;146:477-92.

Apfel S (2002) Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? *Int Rev Neurobiol*
5 50:393-413.

Barker P (1998) p75NTR: A study in contrasts. *Cell Death Differ* 5:346-356.

Bhakar A, Howell J, Paul C, Salehi A, Becker E, Said F, Bonni A, Barker P (2003) Apoptosis induced by p75NTR overexpression requires Jun kinase-dependent phosphorylation of Bad. *J Neurosci* 23:11373-11381.

10 Burstein D, Greene L (1978) Evidence for RNA synthesis-dependent and -independent pathways in stimulation of neurite outgrowth by nerve growth factor. *Proc Natl Acad Sci U S A* 75:6059-6063.

Chao M (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nat Rev Neurosci* 4:299-309.

15 Faden AI, Stoica B. Neuroprotection: challenges and opportunities. *Arch Neurol.* 2007 Jun;64(6):794-800.

Foehr E, Lin X, O'Mahony A, Gelezianas R, Bradshaw R, Greene W (2000) NF-kappa B signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells. *J Neurosci* 20:7556-7563.

20 Frade J (2005) Nuclear translocation of the p75 neurotrophin receptor cytoplasmic domain in response to neurotrophin binding. *J Neurosci* 25:1407-1411.

Gentry J, Casaccia-Bonnel P, Carter B (2000) Nerve growth factor activation of nuclear factor kappaB through its p75 receptor is an anti-apoptotic signal in RN22 schwannoma cells. *J Biol Chem* 275:7558-7565.

25 Ghosh S, May M, Kopp E (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. *Annu Rev Immunol* 16:225-260.

Greene L, Tischler A (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. *Proc Natl Acad Sci U S A* 73:2424-2428.

30 Hellweg R, Ziegenhorn A, Heuser I, Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. *Pharmacopsychiatry.* 2008 Mar;41(2):66-71.

- Huang E, Reichardt L (2003) Trk receptors: roles in neuronal signal transduction. *Annu Rev Biochem* 72:609-642. Epub 2003 Mar 2027.
- Kaplan D, Miller F (2000) Neurotrophin signal transduction in the nervous system. *Curr Opin Neurobiol* 10:381-391.
- 5 Levi-Montalcini R (1987) The nerve growth factor 35 years later. *Science* 237:1154-1162.
- Lewin G, Barde Y (1996) Physiology of the neurotrophins. *Annu Rev Neurosci* 19:289-317.
- Longo F, Manthorpe M, Xie Y, Varon S (1997) Synthetic NGF peptide
10 derivatives prevent neuronal death via a p75 receptor-dependent mechanism. *J Neurosci Res* 48:1-17.
- Longo FM, Yang T, Knowles JK, Xie Y, Moore LA, Massa SM. Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer's disease mechanisms. *Curr Alzheimer Res.* 2007 Dec;4(5):503-6.
- 15 Maliartchouk S, Debeir T, Beglova N, Cuello A, Gehring K, Saragovi H (2000a) Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action. *J Biol Chem* 275:9946-9956.
- Maliartchouk S, Feng Y, Ivanisevic L, Debeir T, Cuello A, Burgess K, Saragovi H (2000b) A designed peptidomimetic agonistic ligand of TrkA nerve
20 growth factor receptors. *Mol Pharmacol* 57:385-391.
- Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, Sepulcre J, Moreno B, Gonzalez Z, Fernandez-Diez B, Melero I, Bendandi M, Villoslada P (2008) IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. *Eur J Immunol* 38:576-586.
- 25 Masip, I.; Ferrándiz-Huertas, C.; García-Martínez, C.; Ferragut, J.; Ferrer-Montiel, A.; Messeguer, A. Synthesis of a Library of 3-Oxopiperazinium and Perhydro-3-oxo-1,4-diazepinium Derivatives and Identification of Bioactive Compounds. *J. Comb. Chem.* 2004, 6, 135-141.
- Miller S, Simon R, NG S, Zuckermann R, Kerr J, Moos W (1994) *Bioorg Med*
30 *Chem Letter* 4:2657-2662.

Moreno B, Hevia H, Santamaria M, Sepulcre J, Munoz J, Garcia-Trevijano E, Berasain C, Corrales F, Avila M, Villoslada P (2006) Methylthioadenosine reverses brain autoimmune disease. *Ann Neurol* 60:323-334.

Palacios R, Comas D, Elorza J, Villoslada P (2008) Genomic regulation of CTLA4 and multiple sclerosis. *J Neuroimmunol* 203:108-115.

Peleshok J, Saragovi H (2006) Functional mimetics of neurotrophins and their receptors. *Biochem Soc Trans* 34:612-617.

Poduslo J, Curran G (1996) Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. *Brain Res Mol Brain Res* 36:280-286.

Price RD, Milne SA, Sharkey J, Matsuoka N. Advances in small molecules promoting neurotrophic function. *Pharmacol Ther.* 2007 Aug;115(2):292-306.

Rabizadeh S, Ye X, Wang J, Bredesen D (1999) Neurotrophin dependence mediated by p75NTR: contrast between rescue by BDNF and NGF. *Cell Death Differ* 6:1222-1227.

Saragovi H, Zaccaro M (2002) Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites. *Curr Pharm Des* 8:2201-2216.

Schulte-Herbrüggen O, Braun A, Rochlitz S, Jockers-Scherübl MC, Hellweg R. Neurotrophic factors--a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? *Curr Med Chem.* 2007;14(22):2318-29.

Sen, S., Roach, S. A convenient Two-step procedure for the Synthesis of Substituted Allylic amines from Allylic Alcohols. *Synthesis*, 1995, 756-758.)

Shi Z, Birman E, Saragovi HU. Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells *in vivo*. *Dev Neurobiol.* 2007 Jun;67(7):884-94.

Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. *Eur Neuropsychopharmacol.* 2005 May;15(3):319-29.

Vajda FJ. Neuroprotection and neurodegenerative disease. *J Clin Neurosci.* 2002 Jan;9(1):4-8.

Villoslada P, Genain C (2004) Role of nerve growth factor and other trophic factors in brain inflammation. *Prog Brain Res* 146:403-414.

Villoslada P, Abel K, Heald N, Goertsches R, Hauser S, Genain C (2001) Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates. *Eur J Immunol* 31:2942-2950.

Villoslada P, Hauser S, Bartke I, Unger J, Heald N, Rosenberg D, Cheung S, Mobley W, Fisher S, Genain C (2000) Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. *J Exp Med* 191:1799-1806.

Williams B, Eriksdotter-Jonhagen M, Granholm A (2006) Nerve growth factor in treatment and pathogenesis of Alzheimer's disease. *Prog Neurobiol* 80:114-128. Epub 2006 Nov 2002.


Youdim MB, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. *Trends Pharmacol Sci.* 2005 Jan;26(1):27-35.

Yoon S, Casaccia-Bonofil P, Carter B, Chao M (1998) Competitive signaling between TrkA and p75 nerve growth factor receptors determines cell survival. *J Neurosci* 18:3273-3281.


Zaccaro M, Ivanisevic L, Perez P, Meakin S, Saragovi H (2001) p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains. *J Biol Chem* 276:31023-31029.

CLAIMS

1. A compound of Formula I:



5 wherein:




10

or form together with the 3-oxopiperazinium ring a fused azoniaspiro [4,5] decane heterocycle;

or a pharmaceutically acceptable salt and/or prodrug thereof.


15 2. A compound of Formula I, according to claim 1, wherein when



then R_2 and R_3 are each one independently CH_3 ;

20


or R_2 is CH_3 and R_3 is



or a pharmaceutically acceptable salt and/or prodrug thereof.

5

3. A compound of Formula I, according to claim 1, wherein when R_1 is




10

then R_2 and R_3 form together with the 3-oxopiperazinium ring a fused azoniaspiro [4,5] decane heterocycle;

15 or a pharmaceutically acceptable salt and/or prodrug thereof.


4. A compound according to any of the claims 1-3, selected among

Formula II:




20

Formula III:



Formula IV:



5

or pharmaceutically acceptable salt and/or prodrug thereof.

5. The compound of any of claims 1 to 4 for use as medicaments.

10 6. The compound according to claim 5 for use as medicaments useful in the prevention or treatment of nerve cell death or damage.

7. The compound according to claim 5 wherein the medicament is a neuroprotective drug.

15

8. The compound according to claim 5 wherein the medicament is useful in the regeneration of nerve cells.

9. The compound according to claim 5 wherein the medicament is a neuroenhancing drug.

20

10. The compound according to claim 5 wherein the medicament is useful in the prevention or treatment of a neurological or psychiatric disease.
11. The compound according to claim 5 wherein the medicament is useful in the prevention or treatment of a disease selected from: neurological diseases, preferentially neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Friedreich's ataxia, Huntington's disease, Dementia with Lewy bodies, spinal muscular atrophy; nerve inflammation, such as multiple sclerosis and neuromyelitis optica, major depressive disorder, schizophrenia, glaucoma; or peripheral neuropathies, such as diabetic or AIDS neuropathy; and cancer, such as glioblastoma, astrocytoma, meduloblastoma, neurinoma, neuroblastoma, meningioma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, leukemia, acute lymphocytic leukemia, osteosarcoma, hepatocellular carcinoma, ovarian carcinoma, lung adenocarcinoma, and esophagic carcinoma.
12. A pharmaceutical composition, comprising a therapeutically effective amount of at least one compound of any one of claims 1 to 4, or combinations thereof, and further comprising, optionally, at least one pharmaceutically acceptable non-active ingredient, preferably at least one excipient and/or carrier.
13. Use of the compound of any one of claims 1 to 4 as an active ingredient in the manufacture of a medicament for the prevention or treatment of nerve cell death or damage.
14. Use of the compound of any one of claims 1 to 4 as an active ingredient in the manufacture of a neuroprotective medicament.
15. Use of the compound of any one of claims 1 to 4 as an active ingredient in the manufacture of a medicament for the regeneration of nerve cells.

16. Use of the compound of any one of claims 1 to 4 as an active ingredient in the manufacture of a medicament for the prevention or treatment of a neurological or psychiatric disease
- 5 17. Use of the compound of any one of claims 1 to 4 as an active ingredient in the manufacture of a medicament for the prevention or treatment of a disease selected from: neurological diseases, preferentially neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Friedreich's ataxia, Huntington's disease, Dementia with Lewy bodies, spinal
10 muscular atrophy; nerve inflammation, such as multiple sclerosis and neuromyelitis optica, major depressive disorder, schizophrenia, glaucoma; peripheral neuropathies, such as diabetic or AIDS neuropathy; and cancer, such as glioblastoma, astrocytoma, meduloblastoma, neurinoma, neuroblastoma, meningioma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, leukemia, acute lymphocytic leukemia ,
15 osteosarcoma, hepatocellular carcinoma, ovarian carcinoma, lung adenocarcinoma , esophagic carcinoma.
18. A method of prevention or treatment of nerve cell death or damage comprising administering to a subject in need thereof an effective amount of the compound of any
20 one of claims 1 to 4; or of the pharmaceutical composition of claim 12.
19. A method of neuroprotection comprising administering to a subject in need thereof an effective amount of the compound of any one of claims 1 to 4; or of the pharmaceutical composition of claim 12.
25
20. A method of regenerating nerve cells comprising administering to a subject in need thereof an effective amount of the compound of any one of claims 1 to 4; or of the pharmaceutical composition of claim 12.
- 30 21. A method of prevention or treatment of a disease comprising administering to a subject in need thereof an effective amount of the compound of any one of claims 1 to 4; or of the pharmaceutical composition of claim 12, wherein the disease is selected

from: neurological diseases, preferentially neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Friedreich's ataxia, Huntington's disease, Dementia with Lewy bodies, spinal muscular atrophy; nerve inflammation, such as multiple sclerosis and neuromyelitis optica, major depressive disorder, schizophrenia, glaucoma; peripheral neuropathies, such as diabetic or AIDS neuropathy; and cancer, such as glioblastoma, astrocytoma, meduloblastoma, neurinoma, neuroblastoma, meningioma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, leukemia, acute lymphocytic leukemia, osteosarcoma, hepatocellular carcinoma, ovarian carcinoma, lung adenocarcinoma, esophagic carcinoma.

22. A method of treating a disease responsive to the stimulation of the activity of nerve growth factor, or a nerve growth factor receptor, in a mammal suffering from lack of stimulation thereof, comprising administering an effective amount a compound of any one of claims 1-4, or a pharmaceutically acceptable salt or prodrug thereof.

23. A compound of any one of claims 1-4, or a pharmaceutically acceptable salt or prodrug thereof, for use in stimulating the activity of nerve growth factor, or a nerve growth factor receptor.

20

24. A method of stimulating nerve growth factor receptor activity in a subject in need thereof, comprising administering a compound of any one of claims 1-4, or a pharmaceutically acceptable salt or prodrug thereof.

25. The method of claim 24, wherein the nerve growth factor receptor is TrkA receptor or p75 receptor.

26. A method of preparing a pharmaceutical composition, comprising admixing an effective amount of a compound of any one of claims 1-4, or a pharmaceutically acceptable salt or prodrug thereof, with a pharmaceutically acceptable carrier.

1/2




FIG. 1

2/2




FIG. 2

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2010/002340

A. CLASSIFICATION OF SUBJECT MATTER INV. C07D241/08 C07D403/12 C07D471/10 A61K31/496 A61K31/499 A61K31/495 A61P25/28 ADD. According to International Patent Classification (IPC) or to both national classification and IPC								
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, CHEM ABS Data								
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category*</th> <th style="width: 70%; padding: 5px;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="width: 20%; padding: 5px;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;"> MASIP I ET AL: "Synthesis of a Library of 3-Oxopiperazinium and Perhydro-3-oxo-1,4-diazepinium Derivatives and Identification of Bioactive Compounds", JOURNAL OF COMBINATORIAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD- DOI:10.1021/CC030002Q, vol. 61, no. 1, 1 January 2004 (2004-01-01), pages 135-141, XP008101472, ISSN: 1520-4766 [retrieved on 2003-11-18] Scheme 1. Figure 2, amines A4 and A9. Figure 3, amines A14, A16 and A17. figures 3,4; table 1 ----- -/-- </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-26</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	MASIP I ET AL: "Synthesis of a Library of 3-Oxopiperazinium and Perhydro-3-oxo-1,4-diazepinium Derivatives and Identification of Bioactive Compounds", JOURNAL OF COMBINATORIAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD- DOI:10.1021/CC030002Q, vol. 61, no. 1, 1 January 2004 (2004-01-01), pages 135-141, XP008101472, ISSN: 1520-4766 [retrieved on 2003-11-18] Scheme 1. Figure 2, amines A4 and A9. Figure 3, amines A14, A16 and A17. figures 3,4; table 1 ----- -/--	1-26
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.						
X	MASIP I ET AL: "Synthesis of a Library of 3-Oxopiperazinium and Perhydro-3-oxo-1,4-diazepinium Derivatives and Identification of Bioactive Compounds", JOURNAL OF COMBINATORIAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD- DOI:10.1021/CC030002Q, vol. 61, no. 1, 1 January 2004 (2004-01-01), pages 135-141, XP008101472, ISSN: 1520-4766 [retrieved on 2003-11-18] Scheme 1. Figure 2, amines A4 and A9. Figure 3, amines A14, A16 and A17. figures 3,4; table 1 ----- -/--	1-26						
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.								
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family								
Date of the actual completion of the international search 1 February 2011	Date of mailing of the international search report 08/02/2011							
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Von Daacke, Axel							

INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2010/002340

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/02372 A1 (VERTEX PHARMA [US]; LAUFFER DAVID [US]; LEDFORD BRIAN [US]) 11 January 2001 (2001-01-11) the whole document -----	1-26

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2010/002340

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 0102372	A1	11-01-2001	AU 5919900 A	22-01-2001
			EP 1196395 A1	17-04-2002
			JP 2003503482 T	28-01-2003
